Building on these results, a phase I clinical trial (NCT03153410) using the combination of IMC-CS4 (CSF1R mAb) with GVAX and anti-PD-1 is ongoing for patients with borderline resectable pancreatic cancer. This evidence concerns the gene CSF1R and pancreatic neoplasm.